10 Octobre 2018

Making enough money to survive long enough to get a product to market can be tough for any biotech, but even more so for companies operating in the industrial space, where it can be less easy to predict development time and potential financial returns. At our recent Refresh event in Paris, Emmanuel Petiot, CEO of Deinove and veteran of industrial biotech giant Novozymes passed on his advice on how to navigate this sometimes rocky road.

Montpellier-based Deinove develops products using genetically modified extremophile bacteria, most notably the genus Deinococcus, which is known for being resistant to very harsh environmental conditions.